Guangzhou, China
As a leader in the research and development of a new generation of antibody drugs, Biotech has promoted a number of drug candidates into late-stage clinical trials, including Gloriflex® (adalimumab), Pubexi® (bevacizumab), Serarili® (Tocilizumab) has been approved for marketing in China. Tocilizumab (BAT1806) (US trade name: TOFIDENCE) has been approved in the United States. The company has more than 20 different products in clinical stages, among which the oncology field mainly focuses on tumor immunotherapy and antibody drug conjugate (ADC) targeted drug development in the post-PD-1 era. Biotech always regards the well-being of patients as its primary core value, and through innovative research and development, provides patients with safe, effective, affordable and high-quality drugs to meet urgent treatment needs.
No key contacts have been added to this profile yet.
No reviews have been added to this profile yet.
This is the company profile page for Bio-Thera on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
